Sfmg LLC Purchases 60 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Sfmg LLC grew its position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 0.8% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 7,845 shares of the pharmaceutical company’s stock after acquiring an additional 60 shares during the quarter. Sfmg LLC’s holdings in Vertex Pharmaceuticals were worth $3,677,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds have also recently modified their holdings of VRTX. Aveo Capital Partners LLC boosted its holdings in shares of Vertex Pharmaceuticals by 77.3% in the 4th quarter. Aveo Capital Partners LLC now owns 1,076 shares of the pharmaceutical company’s stock worth $438,000 after purchasing an additional 469 shares during the period. Gryphon Financial Partners LLC boosted its holdings in Vertex Pharmaceuticals by 26.5% during the 4th quarter. Gryphon Financial Partners LLC now owns 1,978 shares of the pharmaceutical company’s stock valued at $805,000 after acquiring an additional 414 shares during the period. Trexquant Investment LP boosted its holdings in Vertex Pharmaceuticals by 161.2% during the 4th quarter. Trexquant Investment LP now owns 3,968 shares of the pharmaceutical company’s stock valued at $1,615,000 after acquiring an additional 2,449 shares during the period. Quest Partners LLC purchased a new position in Vertex Pharmaceuticals during the 4th quarter valued at $33,000. Finally, US Bancorp DE boosted its holdings in Vertex Pharmaceuticals by 46.3% during the 4th quarter. US Bancorp DE now owns 19,162 shares of the pharmaceutical company’s stock valued at $7,797,000 after acquiring an additional 6,065 shares during the period. Hedge funds and other institutional investors own 90.96% of the company’s stock.

Vertex Pharmaceuticals Stock Up 0.7 %

Shares of VRTX opened at $462.99 on Wednesday. Vertex Pharmaceuticals Incorporated has a 52 week low of $341.85 and a 52 week high of $510.64. The company has a quick ratio of 2.26, a current ratio of 2.52 and a debt-to-equity ratio of 0.02. The company has a market capitalization of $119.50 billion, a price-to-earnings ratio of 30.04 and a beta of 0.40. The stock’s 50-day moving average price is $481.53 and its 200-day moving average price is $453.10.

Vertex Pharmaceuticals (NASDAQ:VRTX) last issued its earnings results on Thursday, August 1st. The pharmaceutical company reported ($12.83) EPS for the quarter, missing analysts’ consensus estimates of ($12.54) by ($0.29). Vertex Pharmaceuticals had a negative return on equity of 2.45% and a negative net margin of 4.74%. The company had revenue of $2.65 billion during the quarter, compared to analysts’ expectations of $2.66 billion. During the same quarter in the previous year, the company earned $3.53 EPS. The firm’s quarterly revenue was up 6.1% compared to the same quarter last year. On average, sell-side analysts predict that Vertex Pharmaceuticals Incorporated will post -2.14 EPS for the current year.

Analyst Upgrades and Downgrades

A number of equities analysts recently issued reports on VRTX shares. Barclays cut Vertex Pharmaceuticals from an “overweight” rating to an “equal weight” rating and boosted their price objective for the company from $472.00 to $509.00 in a report on Monday, August 5th. Canaccord Genuity Group boosted their price objective on Vertex Pharmaceuticals from $371.00 to $376.00 and gave the company a “sell” rating in a report on Wednesday, July 31st. Argus boosted their price objective on Vertex Pharmaceuticals from $465.00 to $550.00 and gave the company a “buy” rating in a report on Monday, June 17th. Oppenheimer upped their target price on Vertex Pharmaceuticals from $500.00 to $550.00 and gave the stock an “outperform” rating in a report on Monday, August 5th. Finally, Wells Fargo & Company upped their target price on Vertex Pharmaceuticals from $540.00 to $555.00 and gave the stock an “overweight” rating in a report on Monday, June 24th. Three investment analysts have rated the stock with a sell rating, eight have issued a hold rating and sixteen have given a buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $486.36.

Insider Buying and Selling at Vertex Pharmaceuticals

In other Vertex Pharmaceuticals news, CMO Carmen Bozic sold 2,280 shares of the stock in a transaction that occurred on Wednesday, August 7th. The stock was sold at an average price of $476.75, for a total transaction of $1,086,990.00. Following the completion of the transaction, the chief marketing officer now owns 23,259 shares of the company’s stock, valued at $11,088,728.25. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In other Vertex Pharmaceuticals news, CMO Carmen Bozic sold 2,280 shares of the stock in a transaction that occurred on Wednesday, August 7th. The stock was sold at an average price of $476.75, for a total transaction of $1,086,990.00. Following the completion of the transaction, the chief marketing officer now owns 23,259 shares of the company’s stock, valued at $11,088,728.25. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Sangeeta N. Bhatia sold 646 shares of the stock in a transaction that occurred on Friday, August 30th. The shares were sold at an average price of $500.00, for a total value of $323,000.00. Following the completion of the sale, the director now directly owns 4,435 shares of the company’s stock, valued at approximately $2,217,500. The disclosure for this sale can be found here. Insiders sold 31,767 shares of company stock valued at $15,768,284 over the last quarter. 0.20% of the stock is currently owned by insiders.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.